BRCA2 is a gene that helps your cells repair damaged DNA. When it works normally, it acts as a tumor suppressor, catching and fixing the kind of DNA breaks that could otherwise lead to uncontrolled cell growth. When someone inherits a harmful mutation in BRCA2, their cells lose much of this repair ability, which significantly raises the lifetime risk of several cancers, most notably breast and ovarian cancer.
How BRCA2 Protects Your DNA
Every cell in your body sustains thousands of DNA breaks each day from normal metabolism, sunlight, and environmental exposures. Most of these are minor, but double-strand breaks, where both strands of the DNA helix snap, are especially dangerous. Left unrepaired, they can trigger mutations that drive cancer.
BRCA2’s job is to coordinate one of the body’s most precise repair systems, called homologous recombination. When a double-strand break occurs, BRCA2 is recruited to the damage site as part of a multi-protein team. There, it loads a repair protein called RAD51 onto the broken DNA, forming a filament that searches for an intact copy of the sequence to use as a template. Think of it like finding the matching page in a backup copy of a book so you can rewrite the damaged page exactly. Without functional BRCA2, cells fall back on sloppier, error-prone repair methods that introduce new mutations with each fix. Over years, these accumulated errors can push a cell toward cancer.
Cancer Risks for Women
More than 60% of women who inherit a harmful BRCA2 mutation will develop breast cancer during their lifetime, compared to about 13% of women in the general population. The risk of ovarian cancer (which includes fallopian tube and primary peritoneal cancers) is also substantially elevated: 13% to 29% of women with a BRCA2 mutation will develop ovarian cancer, versus roughly 1.2% in the general population.
BRCA2-related breast cancers tend to appear at roughly the same average age as non-hereditary cases, which distinguishes them from BRCA1-related cancers, where diagnosis often comes earlier. For ovarian cancer, BRCA2 carriers are typically diagnosed around age 62, similar to the general population, while BRCA1 carriers tend to be diagnosed about a decade earlier, around age 52.
Cancer Risks for Men
BRCA2 mutations are not just a concern for women. Men who carry a BRCA2 mutation face an 8.6-fold increase in prostate cancer risk by age 65. For men over 65 in certain high-risk subgroups, the lifetime risk of prostate cancer can reach roughly 20%. BRCA2-linked prostate cancers also tend to be more aggressive and appear at a younger age than typical cases.
Male breast cancer, while rare overall, is also linked to BRCA2 mutations. Men with the mutation are advised to begin breast self-exams and clinical breast exams at age 35, with mammography considered starting at age 50. Prostate screening with a PSA blood test is recommended beginning at age 40 for BRCA2 carriers, which is earlier than the general population.
Pancreatic and Other Cancers
Beyond breast, ovarian, and prostate cancers, BRCA2 mutations raise the risk of pancreatic cancer. The lifetime risk is about 3% for women with a BRCA2 mutation, which may sound modest until you consider it represents roughly a five-fold increase over the general population’s risk. BRCA2 carriers also face elevated rates of other cancers, though breast and ovarian remain the most clinically significant.
How BRCA2 Mutations Are Inherited
BRCA2 mutations follow an autosomal dominant inheritance pattern, meaning you only need to inherit one faulty copy (from either parent) for your cancer risk to increase. Each child of a carrier has a 50% chance of inheriting the mutation. About 1 in 277 people in the general population carry a harmful BRCA2 variant.
Certain ethnic groups have much higher carrier rates due to founder effects, where a mutation became common in a population that historically had limited genetic mixing. In people of Ashkenazi Jewish ancestry, roughly 1 in 40 individuals carry a harmful variant in either BRCA1 or BRCA2. This is why genetic testing programs sometimes focus on these populations first, though BRCA2 mutations occur across all ethnicities.
How BRCA2 Differs From BRCA1
BRCA1 and BRCA2 are separate genes on different chromosomes, but they work in the same DNA repair pathway and both raise cancer risk when mutated. The key differences are in the pattern of risk. BRCA1 mutations carry a higher ovarian cancer risk (45% to 60% lifetime) compared to BRCA2 (11% to 35%). BRCA1 mutations also tend to cause breast cancer at a younger age, while BRCA2-related breast cancers appear closer to the age you’d expect in the general population. Both genes are linked to increased prostate and pancreatic cancer risk in carriers.
Risk Reduction Options
For women who learn they carry a BRCA2 mutation, there are several well-studied options to reduce cancer risk. Preventive removal of both breasts (bilateral mastectomy) reduces breast cancer risk by 90% to 95% in carriers. Preventive removal of the ovaries and fallopian tubes not only reduces ovarian cancer risk but has also been shown to improve overall survival, partly because it lowers breast cancer risk as well by reducing estrogen levels.
These are significant surgeries with real quality-of-life implications, and the decision depends heavily on a person’s age, family history, and personal priorities. Enhanced screening is the alternative for those who choose not to pursue surgery: this typically involves breast MRI and mammography starting at a younger age than standard guidelines recommend, often by age 25 to 30.
Targeted Cancer Treatment
One of the most important advances for people with BRCA2 mutations has been the development of a class of drugs called PARP inhibitors. These drugs exploit a concept called synthetic lethality: cancer cells that have already lost their BRCA2-powered repair system depend heavily on a backup repair pathway that uses an enzyme called PARP. Block that backup pathway with a drug, and the cancer cell has no way to fix its DNA at all. Normal cells, which still have one working copy of BRCA2, can manage. Cancer cells cannot, and they die.
Four PARP inhibitors have been approved for treating BRCA-mutated cancers. They are used in ovarian, breast, pancreatic, and prostate cancers, depending on the specific drug and clinical situation. This targeted approach represents a shift from broad chemotherapy toward treatments designed around the specific genetic weakness of a tumor, and it has meaningfully improved outcomes for many BRCA2 carriers with cancer.